Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amatuximab (Primary) ; Cisplatin; Pemetrexed
  • Indications Carcinoma; Malignant-mesothelioma
  • Focus Adverse reactions
  • Acronyms ARTEMIS
  • Sponsors Morphotek

    • Most Recent Events

    • 03 Apr 2022 This trial has been completed in Italy and Germany (End Date: 30 Nov 2018), according to European Clinical Trials Database record.
    • 13 Dec 2018 Status changed from active, no longer recruiting to discontinued due to business reasons
    • 01 Oct 2018 Planned End Date changed from 1 Sep 2018 to 30 Nov 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top